This is an important study after "The Trial of Deferiprone in...

This is an important study after "The Trial of Deferiprone in Parkinson's Disease" published in 2022. ATH434 had to work in a different way than Deferiprone making the patients worse. Kosman, who already had worked with ATH434, then PBT434 ( "The iron chelator, PBT434, modulates transcellular iron trafficking in brain microvascular endothelial cells") with his new tools was the right scientist to find the differences between ATH434 and Deferiprone. Now we have even mitochondria level effect of ATH434 that differs from Deferiprone. The poster tells us: "434 possesses potent antioxidant activity that Dfp does not. This antioxidant activity supports and protects the mitochondria".
We will see perhaps in 5-6 months if this difference makes a difference in the clinical symptoms of MSA patients.